Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the bioequivalence of Alendronate Sodium 70 mg of Dr. Reddy's and Fosamax Tablets 70 mg of Merck \& Co.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)

NCT01012934

Healthy

COMPLETED PHASE1

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

NCT00835406

Healthy

COMPLETED PHASE1

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

NCT00983996

Healthy

COMPLETED PHASE1

Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition

NCT02295046

Healthy

COMPLETED PHASE1

Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions

NCT01132040

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study of Alendronate sodium 70 mg tablets of Dr Reddy's Laboratories Limited, India and Fosamax® tablets of Merck \& Co., Inc., USA, in healthy, adult, human subjects under fasting conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alendronate Sodium

Alendronate Sodium Tablets, 70 mg of Dr. Reddy's

Group Type EXPERIMENTAL

Alendronate Sodium Tablets, 70 mg

Intervention Type DRUG

Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.

Fosamax

Fosamax Tablets 70 mg of Merck \& Company. Inc., USA.

Group Type ACTIVE_COMPARATOR

Alendronate Sodium Tablets, 70 mg

Intervention Type DRUG

Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alendronate Sodium Tablets, 70 mg

Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fosamax Tablets 70 mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy human subjects aged between 18 and 45 years (including both).
2. Subjects with a BMI between 18.5 - 24.9 Kg/m2 but weight not less than 45 Kgs.
3. Female subjects who are postmenopausal or surgically sterile.
4. Female subjects of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD) or abstinence.
5. Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations and serology tests.
6. Subjects having normal 12-lead electrocardiogram (ECG).
7. Subjects having normal chest X-Ray (P/A view).
8. Subjects able to communicate effectively.
9. Subjects willing to given written informed consent and adhere to all the requirements of this protocol.

Exclusion Criteria

1. Subjects having contraindications or hypersensitivity to Alendronate sodium or related drugs.
2. History or presence of any medical condition or disease according the opinion of the physician.
3. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
4. History or presence of significant alcoholism or drug abuse in the past one year.
5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day or consumption of tobacco products).
6. Difficulty with donating blood.
7. Difficulty in swallowing solids like tablets or capsules.
8. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.
9. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
10. Pulse rate less than 50/minute or more than 100/minute.
11. Use of any prescribed medication during last two weeks or OTC medical products during the last one week preceding the first dosing.
12. Major illness during 3 months before screening.
13. Participation in a drug research study within past 3 months.
14. Donation of blood in the past 3 months before screening.
15. Female volunteers demonstrating a positive pregnancy screen.
16. Female volunteers who are currently breast-feeding.
17. Female volunteers with child bearing potential using prohibited contraceptive method (Oral, Injectable or Implantable hormonal agents).

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes